Frank Pallone actually said...

This is an important hearing, not only in terms of what is happening to biosimilars, but just the larger issue of drug pricing.

I worry that this inappropriately treats biosimilars like generic drugs and will disincentivize manufacturers from entering the biosimilars ...

We have seen how our healthcare system has benefitted from the competition that comes with a robust market.

I do worry that it is important in the case of biosimilars or generics that that continue to be a way of reducing drug pricing.